After acquiring the radioresistance phenotype, transcriptome analysis showed that pro‐inflammatory pathways are obviously activated, with IL‐6 as the main participant,19 providing the basis for targeted therapies aiming to block inflammatory pathways to enhance the sensitivity of GBM to radiotherapy. Here, IL6 is linked to glioblastoma.